AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Calcium-activated chloride channel regulator 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

A8K7I4

UPID:

CLCA1_HUMAN

Alternative names:

Calcium-activated chloride channel family member 1; Calcium-activated chloride channel protein 1

Alternative UPACC:

A8K7I4; B2RAV5; O95151; Q5TDF4; Q9UNF6; Q9UPC6

Background:

Calcium-activated chloride channel regulator 1, also known as Calcium-activated chloride channel family member 1, plays a pivotal role in calcium-mediated chloride conductance. It is crucial in goblet cell metaplasia, mucus hypersecretion, and cystic fibrosis, regulating mucus production and secretion. Additionally, it contributes to tissue inflammation regulation in the innate immune response and acts as a potential tumor suppressor.

Therapeutic significance:

Understanding the role of Calcium-activated chloride channel regulator 1 could open doors to potential therapeutic strategies, particularly in treating cystic fibrosis, controlling mucus production, and developing anti-inflammatory treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.